At Mundipharma we are committed to those patients who suffer intense pain and to those healthcare professionals who treat them.

At Mundipharma Spain we are committed to developing a diverse portfolio of medicines and devices that meet societal needs. We aim to conduct our business in an ethical, transparent and responsible way, doing what’s right for our employees and partners, while contributing to the communities within which we operate. We look at things from a different perspective and are experts at identifying and developing the potential of medical innovations to help improve patient’s lives in meaningful ways.

Our responsibility in opioid management
We have a proud, 10 year heritage in pain management in Spain and are committed to enabling healthcare professionals to treat their patients in pain safely and responsibly. As an organisation that distributes opioids, we believe we have a responsibility to take measures to minimize the risk of misuse and abuse of these medicines while not depriving the patients that need them. We recognise that misuse and abuse of pain medications can lead to addiction, overdose and death, and we are aware of the public health risk these potent medications can create, especially when they are diverted, misused and/or abused. That’s why we are committed to reducing the risk of misuse and abuse through a secure supply chain, appropriate education of healthcare professionals, responsible sales and marketing and close collaboration with government authorities and medical organisations.

We fund educational initiatives in line with industry regulations that clearly communicate the facts about opioid medicines in a balanced and responsible manner, outlining both risks and benefits and helping to ensure that our medicines are prescribed only to the right patient for the right reasons. We are also committed to finding new approaches to the management of pain, including research into new mechanisms and medicines with the potential to reduce or avoid the need for opioids. Heroin and opioid addiction is also an emerging problem in our community, and this population is often overlooked. We are encouraged that our medicines also play an important role in addiction treatment programmes to help this under-served community.

Among the products we have developed and marketed are

Tumours are the second main cause of death in industrialised countries and their incidence is on the increase. For this reason, at Mundipharma, our Oncohematology team occupies a privileged position within the company.

We understand the future as a commitment to research and the improvement of diagnostic techniques which enable early detection of pathologies, as well as to permanent development of innovative drugs.

We remain loyal to our commitment to increase not only life expectancy but also quality of life of people who suffer from these diseases. We are working to offer patients innovative drugs for the treatment of lymphomatous meningitis and other proliferative syndromes.

During recent years we have collaborated in the development and marketing of valuable drugs such as.

Asthma is one of the most common respiratory diseases in the world. It is the fourth main cause of absenteeism at work and the main cause of absenteeism at school, above all other chronic diseases, and its incidence is increasing every year.

COPD (chronic obstructive pulmonary disease) is a very common, potentially fatal respiratory disease which alters normal breathing and is not totally reversible. It is estimated that in the year 2005, 3 million people around the world died from this disease.

At Mundipharma, we are currently working on the development of innovative drugs in the fields of asthma and COPD with the aim of helping to improve the quality of life of these patients.

Among the products which we are currently marketing in this area is Flutiform®, a combination for the treatment of asthma using a state-of-the-art device.